Bipolar Disorder News

Prescription opioid dispensing decreased for patients with schizophrenia, as well as those with bipolar disorder, between 2015 and 2019, according to study results presented at NEI Congress.

Latuda use was associated with statistically significant improvements on individual quality-of-life items compared with placebo among patients with bipolar depression.

In a video interview, Lyons Hardy, MS, RN, P-MHNP, discussed a presentation on moving beyond the standard treatment paradigm for bipolar depression given at the American Psychiatric Nurses Association Annual Conference.

Patients with severe mental illness, particularly those with schizophrenia who are insured by Medicaid, have significant social risk factors that may adversely affect overall health, according to a study presented at Psych Congress.

Healio Psychiatry’s five most-viewed stories in October highlight: the mental health effects of sibling bullying, the link between staying up late and suicidal thoughts, and regulatory developments.

A longitudinal study assessing illness progression in patients with bipolar disorder and major depressive disorder found a worsening of patient function with depressive episodes, but an overall improvement in functioning over 5 years.

Alkermes has announced that its schizophrenia/bipolar 1 disorder treatment Lybalvi is now available by prescription in the U.S.

Diagnostic shifts related to bipolar disorder were common, particularly for other affective disorders, according to results of a longitudinal study published in Journal of Clinical Psychiatry.

Caplyta reduced depression symptoms in patients with major depressive episodes linked to bipolar I and bipolar II disorders, according to a phase 3 randomized placebo-controlled trial in American Journal of Psychiatry.

The transmission of psychiatric disorders to first-degree relatives is higher among those related to patients with bipolar disorders, according to data published in The Journal of Clinical Psychiatry.